Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3774

1.

[Tailored therapy in treatment of Helicobacter pylori infectionbasedon clarithromycinsensitivity].

Fan X, Xue Q, Xian HP, Sun YJ, Zhao XT, Wang JT.

Zhonghua Yi Xue Za Zhi. 2019 Sep 24;99(36):2826-2830. doi: 10.3760/cma.j.issn.0376-2491.2019.36.006. Chinese.

PMID:
31550810
2.

Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.

Doan T, Arzika AM, Hinterwirth A, Maliki R, Zhong L, Cummings S, Sarkar S, Chen C, Porco TC, Keenan JD, Lietman TM; MORDOR Study Group.

N Engl J Med. 2019 Jun 6;380(23):2271-2273. doi: 10.1056/NEJMc1901535. No abstract available.

3.

Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa.

Keenan JD, Arzika AM, Maliki R, Boubacar N, Elh Adamou S, Moussa Ali M, Cook C, Lebas E, Lin Y, Ray KJ, O'Brien KS, Doan T, Oldenburg CE, Callahan EK, Emerson PM, Porco TC, Lietman TM.

N Engl J Med. 2019 Jun 6;380(23):2207-2214. doi: 10.1056/NEJMoa1817213.

4.

Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.

Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, Jackson L, Keogh M, Lawrence T, Montgomery AA, Roberts TE, Sprange K, Tan W, Thandi S, White J, Wilson J, Duley L; G-ToG trial team.

Lancet. 2019 Jun 22;393(10190):2511-2520. doi: 10.1016/S0140-6736(18)32817-4. Epub 2019 May 2. Erratum in: Lancet. 2019 Jun 29;393(10191):2590. Lancet. 2019 Jun 20;:. Lancet. 2019 Oct 5;394(10205):1230.

5.

Efficacy of azithromycin 1.5% eyedrops vs oral doxycycline in meibomian gland dysfunction: a randomized trial.

Satitpitakul V, Ratanawongphaibul K, Kasetsuwan N, Reinprayoon U.

Graefes Arch Clin Exp Ophthalmol. 2019 Jun;257(6):1289-1294. doi: 10.1007/s00417-019-04322-1. Epub 2019 Apr 22.

PMID:
31011823
6.

Oral azithromycin and oral doxycycline for the treatment of Meibomian gland dysfunction: A 9-month comparative case series.

De Benedetti G, Vaiano AS.

Indian J Ophthalmol. 2019 Apr;67(4):464-471. doi: 10.4103/ijo.IJO_1244_17.

7.

Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy.

Arévalo Galvis A, Trespalacios Rangel AA, Otero Regino W.

Helicobacter. 2019 Jun;24(3):e12574. doi: 10.1111/hel.12574. Epub 2019 Mar 11.

PMID:
30859680
8.

Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?

Zullo A, Fiorini G, Scaccianoce G, Portincasa P, De Francesco V, Vassallo R, Urban F, Monica F, Mogavero G, Amato A, Vaira D.

J Gastrointestin Liver Dis. 2019 Mar;28(1):11-14. doi: 10.15403/jgld.2014.1121.281.hpy.

9.

Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study.

Wang T, Yang X, Li Y, Li L, Liu J, Ji C, Sun Y, Li Y, Zuo X.

Helicobacter. 2019 Jun;24(3):e12569. doi: 10.1111/hel.12569. Epub 2019 Mar 8.

PMID:
30848868
10.
11.

Randomized, open-label, multicenter study of azithromycin compared with doxycycline for treating anorectal Chlamydia trachomatis infection concomitant to a vaginal infection (CHLAZIDOXY study).

Peuchant O, Lhomme E, Krêt M, Ghezzoul B, Roussillon C, Bébéar C, Perry F, de Barbeyrac B; and the Chlazidoxy study group.

Medicine (Baltimore). 2019 Feb;98(7):e14572. doi: 10.1097/MD.0000000000014572.

12.
13.

Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.

Yurenev GL, Partzvania-Vinogradova EV, Andreev DN, Dicheva DT, Maiev IV.

Ter Arkh. 2018 Aug 27;90(8):33-39. doi: 10.26442/terarkh201890833-39.

PMID:
30701937
14.

Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.

Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV.

Ter Arkh. 2018 Aug 27;90(8):27-32. doi: 10.26442/terarkh201890827-32.

PMID:
30701936
15.

Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention.

Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Barry A, Tapily A, Nikiema F, Yerbanga S, Coumare S, Thera I, Traore A, Milligan P, Tinto H, Doumbo O, Ouedraogo JB, Greenwood B.

N Engl J Med. 2019 Jun 6;380(23):2197-2206. doi: 10.1056/NEJMoa1811400. Epub 2019 Jan 30.

16.

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.

Seddik H, Boutallaka H, Elkoti I, Nejjari F, Berraida R, Berrag S, Loubaris K, Sentissi S, Benkirane A.

Eur J Clin Pharmacol. 2019 May;75(5):639-645. doi: 10.1007/s00228-019-02625-0. Epub 2019 Jan 29.

PMID:
30694338
17.

Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.

Kim JS, Oldenburg CE, Cooley G, Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, West SK, Bailey RL, Keenan JD, Gaynor BD, Porco TC, Lietman TM, Martin DL.

PLoS Negl Trop Dis. 2019 Jan 28;13(1):e0007127. doi: 10.1371/journal.pntd.0007127. eCollection 2019 Jan.

18.

[Jinghuaweikang capsules combined with Quadruple therapy in the treatment of Helicobacter pylori infection:a multicenter,randomized,controlled,clinical study].

Yang Q, Shang Q, Wei GQ, Guo QH, Ka SQ, Zhang ZY, Li FW, Shen XP, Zhang DK.

Zhonghua Yi Xue Za Zhi. 2019 Jan 22;99(4):295-300. doi: 10.3760/cma.j.issn.0376-2491.2019.04.012. Chinese.

PMID:
30669717
19.

Comparison between  daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled  trial.

Shahbazi S, Vahdat Shariatpanahi Z.

Indian J Gastroenterol. 2018 Nov;37(6):550-554. doi: 10.1007/s12664-018-0916-z. Epub 2019 Jan 12.

PMID:
30635887
20.

Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.

Postma DF, Spitoni C, van Werkhoven CH, van Elden LJR, Oosterheert JJ, Bonten MJM.

BMC Infect Dis. 2019 Jan 7;19(1):17. doi: 10.1186/s12879-018-3630-7.

Supplemental Content

Loading ...
Support Center